Consumer medicine information

Fulvestrant Sandoz

Fulvestrant

BRAND INFORMATION

Brand name

Fulvestrant Sandoz

Active ingredient

Fulvestrant

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Fulvestrant Sandoz.

What is in this leaflet

This leaflet answers some of the common questions people ask about FULVESTRANT SANDOZ. It does not contain all the information that is known about FULVESTRANT SANDOZ.

It does not take the place of talking to your doctor or pharmacist.

All medicines have risks and benefits. Your doctor will have weighed the risks of you taking FULVESTRANT SANDOZ against the benefits they expect it will have for you.

If you have any concerns about taking this medicine, ask your doctor or pharmacist.

Keep this leaflet with the medicine. You may need to read it again.

What FULVESTRANT SANDOZ is for

FULVESTRANT SANDOZ is used to treat women who have been through menopause with:

  • hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, locally advanced or metastatic breast cancer who have not been previously treated with endocrine therapy.
  • HR positive, locally advanced or metastatic breast cancer who have progressive disease following prior endocrine (anti-oestrogen or aromatase inhibitor) therapy.

FULVESTRANT SANDOZ stops some of the actions of oestrogen within the body. Oestrogen is a female sex hormone that may help cancer cells grow in women with breast cancer.

FULVESTRANT SANDOZ should only be given to women.

FULVESTRANT SANDOZ is not recommended for use in men or children.

FULVESTRANT SANDOZ does not kill cancer cells, however it stops or slows their growth.

Your doctor will have explained why you are being treated with FULVESTRANT SANDOZ and will determine what dose to give you.

Follow all directions given to you by your doctor. They may differ from the information contained in this leaflet.

Your doctor may prescribe this medicine for another use. Ask your doctor if you want more information.

FULVESTRANT SANDOZ is not addictive.

Before you are given FULVESTRANT SANDOZ

When you must not use it

Do not use FULVESTRANT SANDOZ if you have any allergies to the active ingredient fulvestrant, or any of the other ingredients used in FULVESTRANT SANDOZ.

Do not use FULVESTRANT SANDOZ if you have not reached menopause. We do not have information on its use in women before menopause.

Do not use FULVESTRANT SANDOZ if you are pregnant or breastfeeding. It is not known if it is safe for you to be given it while you are pregnant. It may affect your baby if you are given it at any time during pregnancy. If you can become pregnant, you should use effective contraception while you are being treated with FULVESTRANT SANDOZ and for 2 years after the last dose.

Do not use FULVESTRANT SANDOZ if you are breastfeeding.

FULVESTRANT SANDOZ should not be given to children. There is no information on its use in children.

FULVESTRANT SANDOZ should not be given to men. There is no information on its use in men.

FULVESTRANT SANDOZ injection should only be used if the solution is clear, the package is undamaged and the use by (expiry) date marked on the pack has not been passed.

Before you are given it

You must tell your doctor if:

  1. you have any allergies to
  • any medicines
  • any other substances, such as foods, preservatives or dyes
    If you have an allergic reaction, you may get a skin rash, swelling of the extremities, hayfever, difficulty breathing or feel faint.
  1. you have any of these medical conditions
  • liver problems
  • kidney problems
  • bleeding disorders
  • a low blood platelet count

It may not be safe for you to be given FULVESTRANT SANDOZ if you have any of these conditions.

Taking other medicines

Tell your doctor if you are taking any other medicines, including:

  • tamoxifen or any medicine which contains oestrogen (female sex hormone). These medicines may reduce the effect of FULVESTRANT SANDOZ
  • other medicines used to treat cancer
  • medicines that you buy at the chemist, supermarket or health food shop.

These medicines may affect the way FULVESTRANT SANDOZ works.

Your doctor or pharmacist can tell you what to do if you are taking any of these medicines.

If you have not told your doctor about any of these things, tell them before you are given FULVESTRANT SANDOZ.

How FULVESTRANT SANDOZ is given

The usual dose is 500 mg fulvestrant (two (2) x 250 mg/5 mL injections) given once a month with an additional 500 mg dose given 2 weeks after the initial dose.

Your doctor or nurse will give you FULVESTRANT SANDOZ as a slow intramuscular injection, one into each of your buttocks

Overdose

The doctor or nurse giving you FULVESTRANT SANDOZ will be experienced in its use, so it is unlikely that you will be given too much. If you are concerned that you have been given too much FULVESTRANT SANDOZ, tell your doctor or nurse immediately. Otherwise telephone the Poisons Information Centre (telephone 13 11 26) for advice.

While you are using FULVESTRANT SANDOZ

Things you must do

Be sure to keep all your appointments with your doctor so your progress can be checked.

Tell any other doctors, dentists and pharmacists who are treating you that you have been given FULVESTRANT SANDOZ.

If you are about to be started on any new medicine, tell your doctor, dentist or pharmacist that you have been given FULVESTRANT SANDOZ.

If you go into hospital, please let the medical staff know that you are being treated with FULVESTRANT SANDOZ.

Things to be careful of

Be careful driving or operating machinery until you know how FULVESTRANT SANDOZ affects you.

Some patients may occasionally feel weak, tired or sleepy.

Side effects

Tell your doctor or pharmacist as soon as possible if you do not feel well while you are taking FULVESTRANT SANDOZ.

FULVESTRANT SANDOZ helps most people with breast cancer, but it may have unwanted side-effects in some people.

All medicines can have side effects. Sometimes they are serious, most of the time they are not. You may need medical treatment if you get some of the side effects.

Ask your doctor or pharmacist to answer any questions you may have.

Tell your doctor if you notice any of the following and they worry you:

  • pain or inflammation at the injection site
  • hot flushes
  • headache
  • weakness, tiredness, sleepiness
  • nausea or vomiting
  • diarrhoea
  • loss of appetite
  • skin rash
  • urinary tract infections
  • hypersensitivity, including swelling of the face, lips, tongue and/or throat and hives/welts
  • joint or muscle pain.

These are all possible side effects of FULVESTRANT SANDOZ.

FULVESTRANT SANDOZ may be associated with changes in your blood, urine or liver. Your doctor may want to perform tests from time to time to check on your progress and detect any unwanted side effects.

Tell your doctor if you notice anything else that is making you feel unwell. Some people may get other side effects while being treated with FULVESTRANT SANDOZ.

After using FULVESTRANT SANDOZ

Storage

FULVESTRANT SANDOZ should be stored below 25°C. Your doctor or pharmacist will usually store the medicine for you.

Disposal

Your doctor or pharmacist will dispose of any needles, syringes and FULVESTRANT SANDOZ that may be left over.

Product description

What FULVESTRANT SANDOZ looks like

FULVESTRANT SANDOZ is a clear, colourless to yellow viscous liquid for injection. Each pack contains two (2) x 5 mL pre-filled syringes.

Ingredients

Each FULVESTRANT SANDOZ syringe contains
250mg / 5mL of the active ingredient fulvestrant
plus
ethanol
benzyl alcohol
benzyl benzoate
castor oil

Supplier

FULVESTRANT SANDOZ is sponsored and supplied in Australia by:

Sandoz Pty Ltd
54 Waterloo Road
Macquarie Park NSW 2113
Australia
Tel: 1800 726 369

This leaflet was revised on May 2023.

Australian Registration Number AUST R 323030

Published by MIMS August 2023

BRAND INFORMATION

Brand name

Fulvestrant Sandoz

Active ingredient

Fulvestrant

Schedule

S4

 

1 Name of Medicine

The active ingredient in Fulvestrant Sandoz is fulvestrant.

2 Qualitative and Quantitative Composition

Each pre-filled syringe contains 250 mg fulvestrant in 5 mL solution for injection.
Fulvestrant is a white powder with low aqueous solubility. Only 1 morphological form is known to exist. Fulvestrant is highly lipophilic and does not ionise at physiological pH.
Excipients with known effect. Benzoates and alcohol.
For full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Fulvestrant Sandoz 250 mg/5 mL solution for injection is a pre-filled syringe with clear, colourless to yellow, viscous liquid.

4 Clinical Particulars

4.9 Overdose

There are isolated reports of overdose with fulvestrant in humans. If overdose occurs, this should be managed symptomatically. The acute toxicity of fulvestrant in laboratory animal species is low. Animal studies suggested that no effects, other than those related directly or indirectly to antioestrogenic activity, were evident with higher doses of fulvestrant. In dog studies following oral and intravenous administration, effects on the cardiovascular system (slight elevations of the S-T segment of the ECG [oral] and sinus arrest in one dog [intravenous]) were seen, but these occurred in animals exposed to far higher levels of fulvestrant than those recorded in patients (Cmax > 15 times).
For information on the management of overdose, contact the Poisons Information Centre on 131126 (Australia).

5 Pharmacological Properties

5.3 Preclinical Safety Data

Genotoxicity. Fulvestrant showed no genotoxic potential in bacterial reverse mutation assays, in vitro mouse lymphoma assays, an in vitro chromosome aberration assay in human lymphocytes, and an in vivo micronucleus assay in rats.
Carcinogenicity. A two-year rat oncogenicity study (intramuscular administration with the fulvestrant formulation) showed increased incidence of benign ovarian granulosa cell tumours in females at the high dose, 10 mg/rat/15 days (approx 5-times the human dose based on plasma AUC values). Induction of such tumours is consistent with the pharmacology-related endocrine feedback alteration in gonadotropin levels caused by anti-oestrogen in cycling animals. Therefore this finding is not considered to be clinically relevant to the use of fulvestrant in postmenopausal women with advanced breast cancer.

6 Pharmaceutical Particulars

6.7 Physicochemical Properties

Chemical structure. The chemical name is 7α-[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl]estra-1,3,5(10)-triene-3,17β-diol.
https://stagingapi.mims.com/au/public/v2/images/fullchemgif/CSFULVES.gif CAS number. 129453-61-8.
Molecular formula: C32H47F5O3S.
MW: 606.8.

7 Medicine Schedule (Poisons Standard)

S4 - Prescription Only Medicine.

Summary Table of Changes

https://stagingapi.mims.com/au/public/v2/images/fulltablegif/FULSANST.gif